NAZIA KAZMI, M.S.
Clinical Development Operations Program Leadership Portfolio Execution Operational Excellence
Chicago, IL • 630-***-**** • **********@*****.*** EXECUTIVE PROFILE
Clinical Development Operations and Program Leadership professional with 18+ years of experience advancing global development programs from early development through Phase IV. Recognized for strengthening governance, aligning cross-functional organizations, optimizing CRO partnerships, and translating development strategy into executable operational plans across complex global portfolios. Experienced in portfolio prioritization, resource planning, operational excellence, inspection readiness, registration-enabling programs, and global development execution. Trusted partner to Clinical Development, Regulatory AƯairs, Finance, Safety, and Data Sciences leadership for driving informed decision-making, organizational eƯectiveness, and program performance. PROGRAM & DEVELOPMENT LEADERSHIP HIGHLIGHTS
Global Clinical Development Leadership
Global Protocol Lead & Molecule Lead Experience
IND Readiness & Registration-Enabling Studies
Portfolio Prioritization and Resource Allocation
Startup Acceleration & Study Recovery
CRO & Vendor Oversight
Matrix Team Leadership
Inspection & Database Lock Readiness
AREAS OF EXPERTISE
Portfolio Execution • Executive Governance • Clinical Development Operations • Program Leadership • Resource Planning • Operational Excellence • Cross\-Functional Leadership • Risk Management • CRO Governance • Vendor Strategy • Regulatory Readiness EXPERIENCE
Clinical Operations Consultant May 2026 – Present
Partner with executive leadership teams to establish governance frameworks, strengthen development operations, improve organizational eƯectiveness, and drive execution across clinical development programs.
Guided executive teams through complex Ph II/III delivery challenges by aligning strategy, resources, and program priorities, improving visibility into organizational performance and development objectives.
Established governance structures, CRO transition, and oversight frameworks in Ph II/III trials that strengthened accountability, streamlined communication pathways, and enabled faster decision- making.
Applied lessons learned from prior Ph I programs to create scalable operating approaches that improved process optimization and delivery eƯectiveness.
Advanced startup, maintenance, database lock readiness, and closeout activities through proactive planning and risk mitigation while balancing quality, compliance, and timeline objectives.
Established scalable governance and process frameworks that improved organizational eƯectiveness, strengthened decision\-making, and enhanced execution consistency across development programs. Biogen Associate Director, Clinical Trial Lead September 2025 – May 2026 Provided strategic and operational leadership for global development programs, partnering with Clinical Development, Regulatory AƯairs, Finance, Data Sciences, Safety, and senior leadership teams to drive portfolio priorities, investment decisions, and program execution across the development lifecycle.
Developed scenario-based budgets and resource forecasts that informed portfolio planning, investment decisions, organizational prioritization, and executive development planning.
Led cross-functional execution of a global Phase II/III immunology program, aligning Clinical Operations, Regulatory AƯairs, Safety, Data Management, and external partners around development priorities, risk mitigation, and portfolio objectives.
Partnered with Finance and Clinical Development leadership to evaluate tradeoƯs, anticipate risks, and strengthen program planning decisions.
Strengthened CRO collaboration through a culture of transparency, accountability, and rapid issue resolution, enhancing program execution, improving delivery eƯectiveness, and driving recovery of an at-risk clinical start-up.
Maintained inspection readiness through governance frameworks, quality oversight, and risk-mitigation approaches that protected patient safety, data integrity, and regulatory compliance. Actalent (Stream Bio) Senior Clinical Trial Manager – Global April 2024 – May 2025 Led IND-enabling and readiness activities, coordinated regulatory submission support, and built reporting structures improving operational visibility.
Advanced IND-enabling activities, IND readiness eƯorts, and regulatory submissions by aligning deliverables, vendor activities, and cross-functional stakeholders to development timelines for FIH/Ph I Neurology trial.
Established vendor governance models and partnership frameworks that improved accountability, communication, and shared ownership of development objectives.
Developed executive reporting and governance frameworks that improved leadership visibility into operational risks, milestone readiness, and program performance, enabling more proactive development decisions.
Applied proactive risk-management approaches to identify startup barriers early, implement mitigations, and protect key milestones.
Established scalable operating practices and process improvements that enhanced organizational readiness, operational consistency, and program execution. Day One Bio Senior Clinical Trial Manager – Global September 2023 – February 2024 Provided operational leadership for a Phase II/III pediatric oncology program, balancing quality, budget, timeline, and stakeholder priorities while proactively mitigating risks and supporting organizational objectives.
Drove cross-functional execution while balancing timelines, quality expectations, budget considerations, and organizational priorities.
Anticipated emerging risks and implemented mitigation strategies that protected program objectives and strengthened operational execution.
Seagen / Pfizer Senior Clinical Trial Manager – Global April 2022 – September 2023 Served as Global Protocol Lead and Molecule Lead for complex Ph II/III oncology development programs, providing operational leadership across global teams, CRO partners, and cross-functional stakeholders.
Supported successful execution of a global oncology basket trial by aligning activities across regions, functions, and vendor partners, enabling coordinated delivery within a highly complex environment.
Developed strategies supporting site activation, enrollment planning, and risk mitigation, helping maintain momentum toward critical development milestones.
Applied risk-based planning principles and cross-functional collaboration strategies to anticipate challenges early and maintain continuity across a complex oncology portfolio.
Provided matrix leadership and oversight to Regional Clinical Trial Managers and study teams, strengthening accountability and alignment across global programs.
Directed vendor partnerships through collaborative problem-solving and transparent communication, improving responsiveness, issue resolution, and stakeholder engagement.
Championed quality-focused practices supporting data collection, data review, and inspection readiness, strengthening confidence in development decisions. AbbVie Global Study Lead April 2017 – April 2022 Provided operational leadership across multinational oncology development programs spanning Europe, Asia- Pacific, and Latin America. Partnered with cross-functional stakeholders to strengthen governance, improve inspection readiness, support critical development milestones, and enhance execution consistency across global teams.
Guided global Phase II/III oncology program execution by aligning vendors, regional teams, and functional stakeholders around development priorities, strategic objectives, and emerging risks.
Implemented TMF and inspection-readiness strategies that strengthened compliance, reduced organizational risk, and supported audit preparedness.
Chaired Data Management Committee activities supporting interim analyses and database lock decisions, improving governance around critical development milestones.
Collaborated closely with Data Management and cross-functional stakeholders to strengthen data collection processes, organizational readiness, and database lock preparation.
Developed governance approaches that increased transparency across global teams and improved alignment around business process improvement, quality expectations, and risk management.
Leveraged experience across multiple global development programs to identify best practices, standardize operating approaches, and improve execution consistency across international teams.
Promoted proactive issue identification and resolution practices that strengthened program performance and supported reliable study outcomes across multiple regions. Syneos Health (AbbVie FSP) Clinical Study Manager – Global September 2015 – April 2017 Provided operational leadership for complex global oncology programs, directing startup strategy, vendor governance, risk management, and cross-functional execution across a multinational development portfolio.
Guided protocol development, budgeting, startup planning, vendor oversight, and monitoring strategies supporting global studies.
Identified challenges early and implemented corrective actions that protected timelines and compliance requirements.
Aligned stakeholders and priorities across functions to support successful study delivery. Cepheid Clinical Research Associate February 2015 – September 2015 Conducted site initiation, monitoring, and closeout activities supporting in vitro diagnostic studies.
Conducted site selection, initiation, monitoring, and closeout visits supporting Ph II/III in vitro diagnostic studies.
Strengthened site compliance and performance through investigator training, issue resolution, and proactive communication.
Identified protocol deviations and risks requiring corrective action, contributing to high-quality study delivery.
Earlier Career
Progressed through Clinical Research Associate, Research Coordinator, Research Data Coordinator, and Research Assistant roles supporting oncology, neurology, infectious disease, and translational research programs across academic medical centers, health systems, and industry environments. CLINICAL DEVELOPMENT & PORTFOLIO LEADERSHIP EXPERIENCE Oncology
Targeted Therapies • Brain Tumors • Colorectal Cancer • Breast Cancer Neurology
Parkinson's Disease • Multiple Sclerosis • Epilepsy Early Development & Biologics
First-in-Human (FIH) • Biologics
Infectious Disease
HIV • Hepatitis
Immunology & Autoimmune Disease
Lupus, Crohn’s disease
Additional Therapeutic & Functional Experience
Rare Disease • Vaccines • Pediatrics • Diabetic Wound Care (Phase I) • Patient-Reported Outcomes (PRO) • Health Economics & Outcomes Research (HEOR) • Medical Devices • In Vitro Diagnostics (IVD) DEVELOPMENT OPERATIONS & PROGRAM LEADERSHIP EXPERIENCE
First-in-Human (FIH) Programs
IND Readiness Activities
Long-term Safety Trial Management (Ph IV)
SBIR Submission Preparation
End-of-Phase Meeting Preparation
Registration-Enabling Studies
Global Basket Trial Execution
Study Recovery & Rescue Initiatives (including CRO/vendor turnover)
Inspection Readiness
Database Lock Readiness
Global Study Start-Up, Maintenance & Closeout
Clinical Development Programs Across 18+ Countries
Studies Ranging from Early-Phase Programs to Multinational Trials Involving 250+ Sites
Enrollment Targets Ranging from 10 to 500+ Participants EDUCATION
Master of Science (M.S.), Clinical Research
Rush University
Bachelor of Science (B.S.), Environmental Science
Loyola University Chicago